Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, noviembre 19
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Arbutus Biopharma Corp
ABUS
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$4.11
0.06
1.48%
al cierre: Nov 18, 4:00 PM EST
$4.08
0.03
0.74%
Premercado: 4:09 AM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Arbutus Biopharma Financials
Arbutus Biopharma (ABUS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Arbutus Biopharma Q3 EPS $0.30 Beats $(0.03) Estimate, Sales $299.000K Miss $1.388M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $(0.03) by 1100 percent. This is a 850 percent increase over losses of $(0.04) per share from
Benzinga Newsdesk
PRO
Arbutus Biopharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.014M Beat $700.000K Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 400 percent decrease over earnings of $0.01 per share from
Benzinga Newsdesk
PRO
Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $(0.04) by 2275 percent. This is a 769.23 percent increase over losses of $(0.13) per share from
Benzinga Newsdesk
PRO
Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 85.71 percent increase over losses of $(0.07) per share from
Benzinga Newsdesk
PRO
Arbutus Biopharma Q3 EPS $(0.04) Misses $(0.03) Estimate, Sales $529.000K Miss $1.267M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 60 percent increase over losses of $(0.10) per share from
Benzinga Newsdesk
PRO
Arbutus Biopharma Q2 EPS $0.01 Beats $(0.05) Estimate, Sales $10.74M Beat $1.59M Estimate
Benzinga Newsdesk